What's Happening?
NRx Pharmaceuticals has initiated commercial manufacturing of its preservative-free ketamine product in the U.S., anticipating approval under the Generic Drug User Fee Act by Summer 2026. The manufacturing process
uses a blow-fill-seal technique, achieving higher throughput than traditional methods. This product addresses supply shortages of sterile intravenous ketamine, which is listed on the ASHP national drug shortage database. NRx aims to alleviate these shortages with its U.S.-made product.
Why It's Important?
The initiation of manufacturing preservative-free ketamine by NRx Pharmaceuticals is a significant step in addressing the ongoing supply shortages of this critical medication. Ketamine is used for various medical conditions, including depression and PTSD, and its availability is crucial for healthcare providers. By producing a preservative-free version, NRx enhances patient safety and meets regulatory standards. This development is important for the pharmaceutical industry and patients relying on ketamine for treatment.
